Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca/Infinity’s Hsp90 Inhibitor Fails Phase II Prostate Cancer Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III study of IPI-504 in gastrointestinal cancer still on track for later this year.

You may also be interested in...

AstraZeneca/Infinity’s Hsp90 Inhibitor Advances In GIST

Positive PFS data in patients treated with retaspimycin presented at ASCO; Phase III to start in third quarter.

Kosan Buy Puts BMS Front And Center In HSP90 Race, Strengthens Epothilone Position

BMS gains several clinical-stage oncology programs with agreement to acquire Kosan for $190 million.

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts